Pasithea Therapeutics Corp.
KTTA
$0.77
-$0.03-4.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 91.01% | 5.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 95.87% | -18.39% | |||
| Operating Income | -95.87% | 18.39% | |||
| Income Before Tax | -232.88% | 18.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -232.88% | 18.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -232.88% | 18.27% | |||
| EBIT | -95.87% | 18.39% | |||
| EBITDA | -102.64% | 19.75% | |||
| EPS Basic | -94.00% | 38.04% | |||
| Normalized Basic EPS | -14.12% | 38.06% | |||
| EPS Diluted | -94.00% | 38.04% | |||
| Normalized Diluted EPS | -14.12% | 38.06% | |||
| Average Basic Shares Outstanding | 71.57% | 31.95% | |||
| Average Diluted Shares Outstanding | 71.57% | 31.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||